IP Library › Granted Patent US 12,612,408
Granted Patent B2
US 12,612,408 · App. 17/622,579 · Granted Apr 28, 2026

Pyrazolone-fused pyrimidine compound, preparation method for same and applications thereof

Inventors: Qian Wang (Shanghai, CN); Sijie Shu (Shanghai, CN); Guangxin Xia (Shanghai, CN); Hui Ge (Shanghai, CN); Bingbin Zhang (Shanghai, CN); Guoyong Huo (Shanghai, CN); Lin Zhang (Shanghai, CN); Chen Shi (Shanghai, CN); Jiangsong Lou (Shanghai, CN); Chi Zhang (Shanghai, CN); Zhihui Zhang (Shanghai, CN); Yu Mao (Shanghai, CN); Jianxin Yu (Shanghai, CN); Ying Ke (Shanghai, CN); Yanjun Liu (Shanghai, CN)
Assignee: Shanghai Pharmaceuticals Holding Co., Ltd.
C07D487/04A61K31/519A61K45/06A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,612,408
App. No.
17/622,579
Granted
Apr 28, 2026
Kind
B2
Abstract

Disclosed are a pyrazolone-fused pyrimidine compound, a preparation method for same and applications thereof. Provided in the present invention is the pyrazolone-fused pyrimidine compound as represented by formula (II). The compound has improved inhibitory activity with respect to WEE1 kinase.

Claims (351)

1 . A pyrazolone-fused pyrimidine compound represented by formula II, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of the pharmaceutically acceptable salt thereof, a metabolite thereof or a prodrug thereof:

wherein, A is C 3 -C 20 cycloalkyl substituted by one or two R 1 ;

X is CH or N;

R 1 is independently halogen, —OR 1-1 , —SR 1-2 , —CN, —NR 1-3 R 1-4 , —C(═O)R 1-5 , —C(═NR 1-6 )R 1-7 , ═N—O—R 1-9 or “C 2 -C 7 alkenyl, C 2 -C 8 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-8 ;

R 1-1 is independently “C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-1-1 ;

R 1-1-1 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-1-1-1 ”; R 1-1-1-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-2 is independently hydrogen or “C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-2-1 ;

R 1-2-1 is independently hydrogen, halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-2-1-1 ”; R 1-2-1-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 , —C(O)R 1-3-2 , —C(═NR 1-3-3 )NR 1-3-5 R 1-3-6 , S(═O) 2 NR 1-3-7 R 1-3-8 , —C(═O)NR 1-3-9 R 1-3-10 or “C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-3-11 ;

or, R 1-3 and R 1-4 together with a nitrogen atom they are attached to form a C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 1-3-12 ; one or more methylenes in the C 3 -C 14 heterocycloalkyl are optionally and independently substituted by oxygen atom, sulfur atom, sulfinyl, sulfonyl, carbonyl, vinylidene or —N(R 1-3-3 )—; R 1-3-13 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-3-1 and R 1-3-2 are independently “C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl or C 6 -C 10 aryl” optionally substituted by one or two R 1-3-1-1 ; R 1-3-1-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-3-3 is independently hydrogen, —CN, C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl or C 3 -C 14 cycloalkyl;

R 1-3-5 , R 1-3-6 , R 1-3-7 , R 1-3-8 , R 1-3-9 and R 1-3-10 are independently hydrogen, C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl or C 3 -C 14 cycloalkyl;

or, R 1-3-5 and R 1-3-6 together with a nitrogen atom they are attached to form a C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 1-3-5-1 ; one or more methylenes in the C 3 -C 14 heterocycloalkyl are optionally and independently substituted by oxygen atom, sulfur atom, sulfinyl, sulfonyl, carbonyl, vinylidene or —N(R 1-3-5-2 )—; R 1-3-5-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-3-5-2 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

or, R 1-3-7 and R 1-3-8 together with a nitrogen atom they are attached to form a C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 1-3-7-1 ; one or more methylenes in the C 3 -C 14 heterocycloalkyl are optionally and independently substituted by oxygen atom, sulfur atom, sulfinyl, sulfonyl, carbonyl, vinylidene or —N(R 1-3-7-2 )—; R 1-3-7-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-3-7-2 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

or, R 1-3-9 and R 1-3-10 together with a nitrogen atom they are attached to form a C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 1-3-9-1 ; one or more methylenes in the C 3 -C 14 heterocycloalkyl are optionally and independently substituted by oxygen atom, sulfur atom, sulfinyl, sulfonyl, carbonyl, vinylidene or —N(R 1-3-9-2 )—; R 1-3-9-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-3-9-2 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-3-11 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-3-11-1 ”; R 1-3-11-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-3-12 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-3-12-1 ”; R 1-3-12-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-5 is independently hydrogen, —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or “C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-5-4 ;

R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl or C 3 -C 14 cycloalkyl;

or, R 1-5-1 and R 1-5-2 together with a nitrogen atom they are attached to form a C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 1-5-1-1 ; one or more methylenes in the C 3 -C 14 heterocycloalkyl are optionally and independently substituted by oxygen atom, sulfur atom, sulfinyl, sulfonyl, carbonyl, vinylidene or —N(R 1-5-1-2 )—; R 1-5-1-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-5-1-2 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-5-3 is independently hydrogen, C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl;

R 1-5-4 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-5-4-1 ”; R 1-5-4-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-6 is independently hydrogen, —CN, —OH or “C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-6-1 ;

R 1-6-1 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-6-1-1 ”; R 1-6-1-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-7 is independently hydrogen, —OR 1-7-1 , —NR 1-7-2 R 1-7-3 or “C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-7-4 ;

R 1-7-1 is independently hydrogen, C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl;

R 1-7-2 and R 1-7-3 are independently C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl or C 3 -C 14 cycloalkyl;

or, R 1-7-2 and R 1-7-3 together with a nitrogen atom they are attached to form a C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 1-7-2-1 ; one or more methylenes in the C 3 -C 14 heterocycloalkyl are optionally and independently substituted by oxygen atom, sulfur atom, sulfinyl, sulfonyl, carbonyl, vinylidene or —N(R 1-7-2-2 )—; R 1-7-2-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-7-2-2 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-7-4 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-7-4-1 ”; R 1-7-4-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-8 is independently oxo, halogen, —OH, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-8-1 ”; R 1-8-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-9 is independently hydrogen or C 1 -C 7 alkyl;

R 2 is —OR 2-1 , cyano, carboxyl; or “C 2 -C 7 alkyl, C 3 -C 14 cycloalkyl or C 3 -C 14 heterocycloalkyl” optionally substituted by one, two or three R 2-2 ;

R 2-1 is C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl;

R 2-2 is independently halogen, hydroxyl, amino, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 3 -C 14 cycloalkyl or C 3 -C 14 heterocycloalkyl;

the C 3 -C 14 heterocycloalkyl, and C 1 -C 7 heteroaryl independently have 1, 2, 3, or 4 heteroatoms selected from one or more of boron, silicon, oxygen, sulfur, selenium, nitrogen and phosphorus.

2 . The pyrazolone-fused pyrimidine compound represented by formula II according to claim 1 , the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof, wherein, the compound is a pyrazolone-fused pyrimidine compound represented by formula I:

wherein, A is C 3 -C 20 cycloalkyl substituted by one or two R 1 ;

R 1 is independently halogen, —OR 1-1 , —SR 1-2 , —CN, —NR 1-3 R 1-4 , —C(═O)R 1-5 , —C(═NR 1-6 )R 1-7 or “C 2 -C 7 alkenyl, C 2 -C 8 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-8 ;

R 1-1 is independently “C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-1-1 ;

R 1-1-1 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-1-1-1 ”; R 1-1-1-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-2 is independently hydrogen, or “C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-2-1 ;

R 1-2-1 is independently hydrogen, halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-2-1-1 ”; R 1-2- -1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 , —C(O)R 1-3-2 , —C(═NR 1-3-3 )NR 1-3-5 R 1-3-6 , S(═O) 2 NR 1-3-7 R 1-3-8 , —C(═O)NR 1-319 R 1-3-0 or “C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-3-11 ;

or, R 1-3 and R 1-4 together with a nitrogen atom they are attached to form a C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 1-3-12 ; one or more methylenes in the C 3 -C 14 heterocycloalkyl are optionally and independently substituted by oxygen atom, sulfur atom, sulfinyl, sulfonyl, carbonyl, vinylidene or —N(R 1-3-13 )—; R 1-3-13 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-3-1 and R 1-3-2 are independently “C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl or C 6 -C 10 aryl” optionally substituted by one or two R 1-3-1-1 ;

R 1-3-1-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-3-3 is independently hydrogen, —CN, C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl or C 3 -C 14 cycloalkyl;

R 1-3-5 , R 1-3-6 , R 1-3-7 , R 1-3-8 , R 1-3-9 and R 1-3-10 are independently C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl or C 3 -C 14 cycloalkyl;

or, R 1-3-5 and R 1-3-6 together with a nitrogen atom they are attached to form a C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 1-3-5-1 ; one or more methylenes in the C 3 -C 14 heterocycloalkyl are optionally and independently substituted by oxygen atom, sulfur atom, sulfinyl, sulfonyl, carbonyl, vinylidene or —N(R 1-3-5-2 )—; R 1-3-5-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-3-5-2 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

or, R 1-3-7 and R 1-3-8 together with a nitrogen atom they are attached to form a C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 1-3-7-1 ; one or more methylenes in the C 3 -C 14 heterocycloalkyl are optionally and independently substituted by oxygen atom, sulfur atom, sulfinyl, sulfonyl, carbonyl, vinylidene or —N(R 1-3-7-2 )—; R 1-3-7-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-3-7-2 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

or, R 1-3-9 and R 1-3-10 together with a nitrogen atom they are attached to form a C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 1-3-9-1 ; one or more methylenes in the C 3 -C 14 heterocycloalkyl are optionally and independently substituted by oxygen atom, sulfur atom, sulfinyl, sulfonyl, carbonyl, vinylidene or —N(R 1-3-9-2 )—; R 1-3-9-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-3-9-2 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-3-11 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-3-11-1 ”; R 1-3-11-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-3-12 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-3-12-1 ”; R 1-3-12-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-5 is independently hydrogen, —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or “C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-5-4 ;

R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl or C 3 -C 14 cycloalkyl;

or, R 1-5-1 and R 1-5-2 together with a nitrogen atom they are attached to form a C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 1-5-1-1 ; one or more methylenes in the C 3 -C 14 heterocycloalkyl are optionally and independently substituted by oxygen atom, sulfur atom, sulfinyl, sulfonyl, carbonyl, vinylidene or —N(R 1-5-1-2 )—; R 1-5-1-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-5-1-2 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-5-3 is independently hydrogen, C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl;

R 1-5-4 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-5-4-1 ”; R 1-5-4-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-6 is independently hydrogen, —CN, —OH or “C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-6-1 ;

R 1-6-1 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-6-1-1 ”; R 1-6-1-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-7 is independently hydrogen, —OR 1-7-1 , —NR 1-7-2 R 1-7-3 or “C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-7-4 ;

R 1-7-1 is independently hydrogen, C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl;

R 1-7-2 and R 1-7-3 are independently C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl or C 3 -C 14 cycloalkyl;

or, R 1-7-2 and R 1-7-3 together with a nitrogen atom they are attached to form a C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 1-7-2-1 ; one or more methylenes in the C 3 -C 14 heterocycloalkyl are optionally and independently substituted by oxygen atom, sulfur atom, sulfinyl, sulfonyl, carbonyl, vinylidene or —N(R 1-7-2-2 )—; R 1-7-2-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-7-2-2 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-7-4 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-7-4-1 ”; R 1-7-4-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-8 is independently halogen, —OH, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-8-1 ”; R 1-8-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 2 is —OR 2-1 , cyano, carboxyl; or “C 2 -C 7 alkyl, C 3 -C 14 cycloalkyl or C 3 -C 14 heterocycloalkyl” optionally substituted by one, two or three R 2-2 ;

R 2-1 is C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl;

R 2-2 is independently halogen, hydroxyl, amino, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 3 -C 14 cycloalkyl or C 3 -C 14 heterocycloalkyl;

the C 3 -C 14 heterocycloalkyl, and C 1 -C 7 heteroaryl have 1, 2, 3 or 4 heteroatoms independently selected from one or more of boron, silicon, oxygen, sulfur, selenium, nitrogen and phosphorus.

3 . The pyrazolone-fused pyrimidine compound represented by formula II according to claim 1 , the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof, wherein, when A is C 3 -C 20 cycloalkyl substituted by one or two R 1 , the C 3 -C 20 cycloalkyl is C 3 -C 20 monocyclic cycloalkyl, C 3 -C 20 spiro cycloalkyl, C 3 -C 20 fused cycloalkyl or C 3 -C 20 bridged cycloalkyl;

or, when A is C 3 -C 20 cycloalkyl substituted by one or two R 1 , the C 3 -C 20 cycloalkyl is C 3 -C 20 saturated cycloalkyl;

or, when R 1 is independently C 3 -C 14 heterocycloalkyl, the C 3 -C 14 heterocycloalkyl is C 3 -C 14 monocyclic heterocycloalkyl, C 3 -C 14 spiro heterocycloalkyl, C 3 -C 14 fused heterocycloalkyl or C 3 -C 14 bridged heterocycloalkyl;

or, when R 1 is independently C 3 -C 14 heterocycloalkyl, the heteroatom of the C 3 -C 14 heterocycloalkyl is not substituted;

or, when R 1 is independently C 3 -C 14 heterocycloalkyl, the methylene in the C 3 -C 14 heterocycloalkyl is not substituted;

or, when R 1 is independently C 3 -C 14 heterocycloalkyl substituted by one R 1-8 , the C 3 -C 14 heterocycloalkyl is C 3 -C 14 monocyclic heterocycloalkyl, C 3 -C 14 spiro heterocycloalkyl, C 3 -C 14 fused heterocycloalkyl or C 3 -C 14 bridged heterocycloalkyl;

or, when R 1 is independently C 3 -C 14 heterocycloalkyl substituted by one R 1-8 , the heteroatom of the C 3 -C 14 heterocycloalkyl is not substituted except R 1-8 ;

or, when R 1 is independently C 3 -C 14 heterocycloalkyl substituted by one R 1-8 , the methylene in the C 3 -C 14 heterocycloalkyl is not substituted;

or, when R 1-3 and R 1-4 are independently C 1 -C 7 alkyl, the C 1 -C 7 alkyl is C 1 -C 3 alkyl;

or, when R 1-3-1 is independently C 1 -C 7 alkyl, the C 1 -C 7 alkyl is C 1 -C 3 alkyl;

or, when R 1-3-2 is independently C 3 -C 14 cycloalkyl, the C 3 -C 14 cycloalkyl is C 3 -C 14 monocyclic cycloalkyl, C 3 -C 14 spiro cycloalkyl, C 3 -C 14 fused cycloalkyl or C 3 -C 14 bridged cycloalkyl;

or, when R 1-3-2 is C 3 -C 14 cycloalkyl, the C 3 -C 14 cycloalkyl is C 3 -C 14 saturated cycloalkyl;

or, when R 1-5 is independently C 3 -C 14 heterocycloalkyl, the C 3 -C 14 heterocycloalkyl is C 3 -C 14 monocyclic heterocycloalkyl, C 3 -C 14 spiro heterocycloalkyl, C 3 -C 14 fused heterocycloalkyl or C 3 -C 14 bridged heterocycloalkyl;

or, when R 1-5 is independently C 3 -C 14 heterocycloalkyl, the heteroatom of the C 3 -C 14 heterocycloalkyl is not substituted;

or, when R 1-5 is independently C 3 -C 14 heterocycloalkyl, the methylene in the C 3 -C 14 heterocycloalkyl is not substituted;

or, when R 1-5-1 and R 1-5-2 are independently C 1 -C 7 alkyl, the C 1 -C 7 alkyl is C 1 -C 3 alkyl;

or, when R 1-5-1 and R 1-5-2 are independently C 3 -C 14 cycloalkyl, the C 3 -C 14 cycloalkyl is C 3 -C 14 monocyclic cycloalkyl, C 3 -C 14 spiro cycloalkyl, C 3 -C 14 fused cycloalkyl or C 3 -C 14 bridged cycloalkyl;

or, when R 1-5-1 and R 1-5-2 are independently C 3 -C 14 cycloalkyl, the C 3 -C 14 cycloalkyl is C 3 -C 14 saturated cycloalkyl;

or, when R 1-5-3 is independently C 1 -C 7 alkyl, the C 1 -C 7 alkyl is C 1 -C 3 alkyl;

or, when R 1-9 is independently C 1 -C 7 alkyl, the C 1 -C 7 alkyl is C 1 -C 3 alkyl;

or, when R 2 is C 2 -C 7 alkyl optionally substituted by one, two or three R 2-2 , the C 2 -C 7 alkyl is C 2 -C 4 alkyl;

or, when R 2 is C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 2-2 , the C 3 -C 14 heterocycloalkyl is C 3 -C 14 monocyclic heterocycloalkyl, C 3 -C 14 spiro heterocycloalkyl, C 3 -C 14 fused heterocycloalkyl or C 3 -C 14 bridged heterocycloalkyl;

or, when R 2 is C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 2-2 , the heteroatom of the C 3 -C 14 heterocycloalkyl is not substituted except R 2-2 ;

or, when R 2 is C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 2-2 , the methylene in the C 3 -C 14 heterocycloalkyl is not substituted;

or, a ratio of each isomer in the pyrazolone-fused pyrimidine compound represented by formula II is equal;

or, the atoms in the pyrazolone-fused pyrimidine compound represented by formula II, the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof all exist in their natural abundance.

4 . The pyrazolone-fused pyrimidine compound represented by formula II according to claim 3 , the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof, wherein, when A is C 3 -C 20 cycloalkyl substituted by one or two R 1 , the C 3 -C 20 cycloalkyl is C 3 -C 20 monocyclic cycloalkyl, C 3 -C 20 monocyclic cycloalkyl is C 3 -C 6 monocyclic cycloalkyl;

or, when A is C 3 -C 20 cycloalkyl substituted by one or two R 1 , the C 3 -C 20 cycloalkyl is C 3 -C 20 bridged cycloalkyl; the C 3 -C 20 bridged cycloalkyl is C 5 -C 8 bridged cycloalkyl;

or, when R 1 is independently C 3 -C 14 heterocycloalkyl, the C 3 -C 14 heterocycloalkyl is C 3 -C 14 monocyclic heterocycloalkyl; the C 3 -C 14 monocyclic heterocycloalkyl is “C 3 -C 9 monocyclic heterocycloalkyl having one or two heteroatoms selected from one or two of N, O and S”;

or, when R 1 is independently C 3 -C 14 heterocycloalkyl substituted by one R 1-8 , the C 3 -C 14 heterocycloalkyl is C 3 -C 14 monocyclic heterocycloalkyl; the C 3 -C 14 monocyclic heterocycloalkyl is the “C 3 -C 9 monocyclic heterocycloalkyl having one or two heteroatoms selected from one or two of N, O and S”;

or, when R 1-3 and R 1-4 are independently C 1 -C 7 alkyl, the C 1 -C 7 alkyl is methyl, ethyl, n-propyl or isopropyl;

or, when R 1-3-1 is independently C 1 -C 7 alkyl, the C 1 -C 7 alkyl is methyl, ethyl, n-propyl or isopropyl;

or, when R 1-3-2 is independently C 3 -C 14 cycloalkyl, the C 3 -C 14 cycloalkyl is C 3 -C 14 monocyclic cycloalkyl; the C 3 -C 14 monocyclic cycloalkyl is C 3 -C 6 monocyclic cycloalkyl;

or, when R 1-5 is independently C 3 -C 14 heterocycloalkyl, the C 3 -C 14 heterocycloalkyl is C 3 -C 14 monocyclic heterocycloalkyl; the C 3 -C 14 monocyclic heterocycloalkyl is “C 3 -C 9 monocyclic heterocycloalkyl having one or two heteroatoms selected from one or two of N, O and S”;

or, when R 1-5-1 and R 1-5-2 are independently C 1 -C 7 alkyl, the C 1 -C 7 alkyl is methyl, ethyl, n-propyl or isopropyl;

or, when R 1-5-1 and R 1-5-2 are independently C 3 -C 14 cycloalkyl, the C 3 -C 14 cycloalkyl is C 3 -C 14 monocyclic cycloalkyl; the C 3 -C 14 monocyclic cycloalkyl is C 3 -C 6 monocyclic cycloalkyl;

or, when R 1-5-3 is independently C 1 -C 7 alkyl, the C 1 -C 7 alkyl is methyl, ethyl, n-propyl or isopropyl;

or, when R 2 is C 2 -C 7 alkyl optionally substituted by one, two or three R 2-2 , the C 2 -C 7 alkyl is ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;

or, when R 2 is independently C 3 -C 14 heterocycloalkyl substituted by one, two or three R 22 , the C 3 -C 14 heterocycloalkyl is C 3 -C 14 monocyclic heterocycloalkyl; the C 3 -C 14 monocyclic heterocycloalkyl is “C 3 -C 9 monocyclic heterocycloalkyl having one or two heteroatoms selected from one or two of N, O and S”;

or, a ratio of each isomer in the pyrazolone-fused pyrimidine compound represented by formula I is equal;

or, the atoms in the pyrazolone-fused pyrimidine compound represented by formula I, the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof all exist in their natural abundance.

5 . The pyrazolone-fused pyrimidine compound represented by formula II according to claim 4 , the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof, wherein, when A is C 3 -C 20 cycloalkyl substituted by one or two R 1 , the C 3 -C 20 cycloalkyl is C 3 -C 20 monocyclic cycloalkyl, the C 3 -C 20 monocyclic cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

or, when A is C 3 -C 20 cycloalkyl substituted by one or two R 1 , the C 3 -C 20 cycloalkyl is C 3 -C 20 bridged cycloalkyl; the C 3 -C 20 bridged cycloalkyl is

or, when R 1 is independently C 3 -C 14 heterocycloalkyl, the C 3 -C 14 heterocycloalkyl is C 3 -C 14 monocyclic heterocycloalkyl; the C 3 -C 14 monocyclic heterocycloalkyl is

or, when R 1 is independently C 3 -C 14 heterocycloalkyl substituted by one R 1-8 , the C 3 -C 14 heterocycloalkyl substituted by one R 1-8 is

or, when R 1-3-2 is C 3 -C 14 cycloalkyl, the C 3 -C 14 cycloalkyl is C 3 -C 14 monocyclic cycloalkyl; the C 3 -C 14 monocyclic cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

or, when R 1-5 is independently C 3 -C 14 heterocycloalkyl, the C 3 -C 14 heterocycloalkyl is C 3 -C 14 monocyclic heterocycloalkyl; the C 3 -C 14 monocyclic heterocycloalkyl is

or, when R 1-5-1 and R 1-5-2 are independently C 3 -C 14 cycloalkyl, the C 3 -C 14 cycloalkyl is C 3 -C 14 monocyclic cycloalkyl; the C 3 -C 14 monocyclic cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

or, when R 2 is C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 2-2 , the C 3 -C 14 heterocycloalkyl is C 3 -C 14 monocyclic heterocycloalkyl; the C 3 -C 14 monocyclic heterocycloalkyl is oxetan-3-yl.

6 . The pyrazolone-fused pyrimidine compound represented by formula II according to claim 1 , the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof, wherein, when A is C 3 -C 20 cycloalkyl substituted by one R 1 , the A is

or, when R 1 is independently C 3 -C 14 heterocycloalkyl, the C 3 -C 14 heterocycloalkyl is C 3 -C 14 monocyclic heterocycloalkyl; the C 3 -C 14 monocyclic heterocycloalkyl is

or, when R 1-5 is independently C 3 -C 14 heterocycloalkyl, the C 3 -C 14 heterocycloalkyl is C 3 -C 14 monocyclic heterocycloalkyl; the C 3 -C 14 monocyclic heterocycloalkyl is

or, when R 2 is C 2 -C 7 alkyl substituted by one R 2-2 , R 2-2 is hydroxyl; the C 2 -C 7 alkyl substituted by one R 2-2 is

or, when R 2 is C 3 -C 14 heterocycloalkyl substituted by one R 2-2 , R 2-2 is halogen or hydroxyl; the C 3 -C 14 heterocycloalkyl substituted by one R 2-2 is

7 . The pyrazolone-fused pyrimidine compound represented by formula II according to claim 6 , the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof, wherein, when A is C 3 -C 20 cycloalkyl substituted by one R 1 ; the A is

8 . The pyrazolone-fused pyrimidine compound represented by formula II according to claim 1 , the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof, wherein, A is C 3 -C 20 cycloalkyl substituted by one R 1 ;

or, X is N;

or, R 1 is independently cyano, halogen, —NR 1-3 R 1-4 , —C(═O)R 1-5 , —C(═NR 1-6 )R 1-7 , ═N—O—R 1-9 , C 1 -C 7 heteroaryl or “C 3 -C 14 heterocycloalkyl” optionally substituted by one R 1-8 ;

or, R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 , —C(═O)R 1-3-2 , —C(═NR 1-3-3 )NR 1-3-5 R 1-3-6 , or C 1 -C 7 alkyl; R 1-3-1 and R 1-3-2 are independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-3-3 is hydrogen; R 1-3-5 and R 1-3-6 are hydrogen;

or, R 1-5 is independently —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or C 3 -C 14 heterocycloalkyl; R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-5-3 is independently hydrogen or C 1 -C 7 alkyl;

or, R 1-8 is independently oxo;

or, R 2 is “C 2 -C 7 alkyl, C 3 -C 14 cycloalkyl or C 3 -C 14 heterocycloalkyl” optionally substituted by one, two or three R 2-2 ; R 2-2 is independently halogen or hydroxyl.

9 . The pyrazolone-fused pyrimidine compound represented by formula II according to claim 1 , the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof, wherein, A is C 3 -C 20 cycloalkyl substituted by one R 1 ;

or, R 1 is independently cyano, halogen, —NR 1-3 R 1-4 , —C(═O)R 1-5 , —C(═NR 1-6 )R 1-7 , C 1 -C 7 heteroaryl or C 3 -C 14 heterocycloalkyl;

or, R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 or C 1 -C 7 alkyl; R 1-3-1 is independently C 1 -C 7 alkyl;

or, R 1-5 is independently —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or C 3 -C 14 heterocycloalkyl; R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-5-3 is independently hydrogen or C 1 -C 7 alkyl;

or, R 2 is “C 2 -C 7 alkyl, C 3 -C 14 cycloalkyl or C 3 -C 14 heterocycloalkyl” optionally substituted by one, two or three R 2-2 ; R 2-2 is independently halogen or hydroxyl.

10 . The pyrazolone-fused pyrimidine compound represented by formula II according to claim 9 , the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof, wherein, R 1 is independently —NR 1-3 R 1-4 , —C(═O)R 1-5 or C 3 -C 14 heterocycloalkyl;

or, R 1-5 is independently —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or C 3 -C 14 heterocycloalkyl; R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-5-3 is hydrogen;

or, R 2 is “C 2 -C 7 alkyl or C 3 -C 14 heterocycloalkyl substituted by one R 2-2 ”; R 2-2 is halogen or hydroxyl.

11 . The pyrazolone-fused pyrimidine compound represented by formula II according to claim 1 , the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof, wherein, the pyrazolone-fused pyrimidine compound represented by formula II is a compound of any one of scheme (1), scheme (2), scheme (3), scheme (4), scheme (5), scheme (6), scheme (7), scheme (8) or scheme (9):

scheme (1):

A is

 substituted by one or two R 1 ;

R 1 is independently halogen, —CN, —NR 1-3 R 1-4 , —C(═O)R 1-5 , —C(═NR 1-6 )R 1-7 or “C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-8 ;

R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 , —C(═O)R 1-3-2 , —C(═NR 1-3-3 )NR 1-3-5 R 1-3-6 , —S(═O) 2 NR 1-3-7 R 1-3-8 , —C(═O)NR 1-3-9 R 1-3-10 or “C 1 -C 7 alkyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-3-11 ;

R 1-3-1 and R 1-3-2 are independently “C 1 -C 7 alkyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl or C 6 -C 10 aryl” optionally substituted by one or two R 1-3-1-1 ; R 1-3-1-1 is independently C 1 -C 7 alkyl;

R 1-3-3 is independently hydrogen;

R 1-3-5 , R 1-3-6 , R 1-3-7 , R 1-3-8 , R 1-3-9 and R 1-3-10 are independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-3-11 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-3-11-1 ”; R 1-3-11-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-5 is independently hydrogen, —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or “C 1 -C 7 alkyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-5-4 ;

R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-5-3 is independently hydrogen, C 1 -C 7 alkyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl;

R 1-5-4 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-5-4-1 ”; R 1-5-4-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-6 is independently hydrogen, —CN, —OH;

R 1-7 is independently hydrogen, —NR 1-7-2 R 1-7-3 ;

R 1-7-2 and R 1-7-3 are independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

or, R 1-7-2 and R 1-7-3 together with a nitrogen atom they are attached to form a C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 1-7-2-1 ; one or more methylenes in the C 3 -C 14 heterocycloalkyl are optionally and independently substituted by oxygen atom, sulfur atom;

R 1-7-2-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-8 is independently halogen, —OH, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-8-1 ”; R 1-8-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 2 is “C 2 -C 7 alkyl, C 3 -C 14 cycloalkyl or C 3 -C 14 heterocycloalkyl” optionally substituted by one, two or three R 2-2 ;

R 2-2 is independently halogen or hydroxyl;

the C 3 -C 14 heterocycloalkyl, and C 1 -C 7 heteroaryl have 1, 2, 3, or 4 heteroatoms independently selected from one or more of boron, silicon, oxygen, sulfur, selenium, nitrogen and phosphorus;

scheme (2):

A is C 3 -C 20 cycloalkyl substituted by one or two R 1 ;

R 1 is independently cyano, halogen, —NR 1-3 R 1-4 , —C(═O)R 1-5 , —C(═NR 1-6 )R 1-7 , C 1 -C 7 heteroaryl or C 3 -C 14 heterocycloalkyl;

R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 or C 1 -C 7 alkyl; R 1-3-1 is independently C 1 -C 7 alkyl;

R 1-5 is independently —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or C 3 -C 14 heterocycloalkyl; R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-5-3 is independently hydrogen or C 1 -C 7 alkyl;

R 2 is “C 2 -C 7 alkyl or C 3 -C 14 heterocycloalkyl substituted by one R 2-2 ”; R 2-2 is halogen or hydroxyl;

scheme (3):

A is C 3 -C 20 cycloalkyl substituted by one R 1 ;

R 1 is —NR 1-3 R 1-4 , —C(═O)R 1-5 or C 3 -C 14 heterocycloalkyl;

R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 or C 1 -C 7 alkyl; R 1-3-1 is independently C 1 -C 7 alkyl;

R 1-5 is —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or C 3 -C 14 heterocycloalkyl; R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-5-3 is hydrogen or C 1 -C 7 alkyl;

R 2 is “C 2 -C 7 alkyl or C 3 -C 14 heterocycloalkyl substituted by one R 2-2 ”; R 2-2 is hydroxyl;

scheme (4):

A is C 3 -C 20 cycloalkyl substituted by one R 1 ;

R 1 is —NR 1-3 R 1-4 , —C(═O)R 1-5 or C 3 -C 14 heterocycloalkyl;

R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 or C 1 -C 7 alkyl; R 1-3-1 is independently C 1 -C 7 alkyl;

R 1-5 is —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or C 3 -C 14 heterocycloalkyl; R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-5-3 is hydrogen;

R 2 is “C 2 -C 7 alkyl or C 3 -C 14 heterocycloalkyl substituted by one R 2-2 ”; R 2-2 is hydroxyl;

scheme (5):

A is

R 1 is —NR 1-3 R 1-4 , —C(═O)R 1-5 or C 3 -C 14 heterocycloalkyl;

R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 or C 1 -C 7 alkyl; R 1-3-1 is independently C 1 -C 7 alkyl;

R 1-5 is —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or C 3 -C 14 heterocycloalkyl; R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-5-3 is hydrogen or C 1 -C 7 alkyl;

R 2 is “C 2 -C 7 alkyl or C 3 -C 14 heterocycloalkyl substituted by one R 2-2 ”; R 2-2 is hydroxyl;

scheme (6):

A is

R 1 is —NR 1-3 R 1-4 , —C(═O)R 1-5 or C 3 -C 14 heterocycloalkyl;

R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 or C 1 -C 7 alkyl; R 1-3-1 is independently C 1 -C 7 alkyl;

R 1-5 is —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or C 3 -C 14 heterocycloalkyl; R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-5-3 is hydrogen or C 1 -C 7 alkyl;

R 2 is

scheme (7):

A is

 substituted by one or two R 1 ;

X is CH or N;

R 1 is independently halogen, —CN, —NR 1-3 R 1-4 , —C(═O)R 1-5 , —C(═NR 1-6 )R 1-7 , ═N—O—R 1-9 or “C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-8 ;

R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 , —C(═O)R 1-3-2 , —C(═NR 1-3-3 )NR 1-3-5 R 1-3-6 , —S(═O) 2 NR 1-3-7 R 1-3-8 , —C(═O)NR 1-3-9 R 1-3-10 or “C 1 -C 7 alkyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-3-11 ;

R 1-3-1 and R 1-3-2 are independently “C 1 -C 7 alkyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl or C 6 -C 10 aryl optionally substituted” by one or two R 1-3-1-1 ; R 1-3-1-1 is independently C 1 -C 7 alkyl;

R 1-3-3 is independently hydrogen;

R 1-3-5 , R 1-3-6 , R 1-3-7 , R 1-3-8 , R 1-3-9 and R 1-3-10 are independently hydrogen, C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-3-11 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-3-11-1 ”; R 1-3-11-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-5 is independently hydrogen, —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or “C 1 -C 7 alkyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl” optionally substituted by one, two or three R 1-5-4 ;

R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-5-3 is independently hydrogen, C 1 -C 7 alkyl, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl or C 1 -C 7 heteroaryl;

R 1-5-4 is independently halogen, hydroxyl, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-5-4-1 ”; R 1-5-4-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-6 is independently hydrogen, —CN, —OH;

R 1-7 is independently hydrogen, —NR 1-7-2 R 1-7-3 ;

R 1-7-2 and R 1-7-3 are independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

or, R 1-7-2 and R 1-7-3 together with a nitrogen atom they are attached to form a C 3 -C 14 heterocycloalkyl optionally substituted by one, two or three R 1-7-2-1 ; one or more methylenes in the C 3 -C 14 heterocycloalkyl are optionally and independently substituted by oxygen atom, sulfur atom; R 1-7-2-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-8 is independently oxo, halogen, —OH, amino, mercapto, cyano, C 1 -C 7 alkyl, C 1 -C 7 alkoxy, C 1 -C 7 alkylthio, C 3 -C 14 cycloalkyl, C 3 -C 14 heterocycloalkyl, C 6 -C 10 aryl, C 1 -C 7 heteroaryl or “amino substituted by one or two R 1-8-1 ”; R 1-8-1 is independently C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-9 is independently hydrogen or C 1 -C 7 alkyl;

R 2 is “C 2 -C 7 alkyl, C 3 -C 14 cycloalkyl or C 3 -C 14 heterocycloalkyl” optionally substituted by one, two or three R 2-2 ;

R 2-2 is independently halogen or hydroxyl;

the C 3 -C 14 heterocycloalkyl, and C 1 -C 7 heteroaryl have 1, 2, 3 or 4 heteroatoms independently selected from one or more of boron, silicon, oxygen, sulfur, selenium, nitrogen and phosphorus;

scheme (8):

A is C 3 -C 20 cycloalkyl substituted by one or two R 1 ;

X is CH or N;

R 1 is independently cyano, halogen, —NR 1-3 R 1-4 , —C(═O)R 1-5 , —C(═NR 1-6 )R 1-7 , ═N—O—R 1-9 , C 1 -C 7 heteroaryl or “C 3 -C 14 heterocycloalkyl” optionally substituted by one R 1-8 ;

R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 , —C(═O)R 1-3-2 , —C(═NR 1-3-3 )NR 1-3-5 R 1-3-6 , or C 1 -C 7 alkyl;

R 1-3-1 and R 1-3-2 are independently C 1 -C 7 alkyl, or C 3 -C 14 cycloalkyl;

R 1-3-3 is hydrogen;

R 1-3-5 and R 1-3-6 are hydrogen;

R 1-5 is independently —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or C 3 -C 14 heterocycloalkyl; R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-5-3 is independently hydrogen or C 1 -C 7 alkyl;

R 1-8 is independently oxo;

R 1-9 is independently hydrogen or C 1 -C 7 alkyl;

R 2 is “C 2 -C 7 alkyl or C 3 -C 14 heterocycloalkyl substituted by one R 2-2 ”; R 2-2 is halogen or hydroxyl;

scheme (9):

A is C 3 -C 20 cycloalkyl substituted by one R 1 ;

X is CH or N;

R 1 is —CN, —NR 1-3 R 1-4 , —C(═O)R 1-5 , ═N—O—R 1-9 or “C 3 -C 14 heterocycloalkyl” optionally substituted by one R 1-8 ;

R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 , —C(═O)R 1-3-2 , —C(═NR 1-3-3 )NR 1-3-5 R 1-3-6 , or C 1 -C 7 alkyl;

R 1-3-1 and R 1-3-2 are independently C 1 -C 7 alkyl, or C 3 -C 14 cycloalkyl;

R 1-3-3 is hydrogen;

R 1-3-5 and R 1-3-6 are hydrogen;

R 1-5 is —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or C 3 -C 14 heterocycloalkyl;

R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-5-3 is independently hydrogen or C 1 -C 7 alkyl;

R 1-8 is independently oxo;

R 1-9 is independently hydrogen or C 1 -C 7 alkyl;

R 2 is “C 2 -C 7 alkyl or C 3 -C 14 heterocycloalkyl substituted by one R 2-2 ”; R 2-2 is hydroxyl;

scheme (10):

A is C 3 -C 20 cycloalkyl substituted by one R 1 ;

X is CH or N;

R 1 is —CN, —NR 1-3 R 1-4 , —C(═O)R 1-5 , ═N—O—R 1-9 , or “C 3 -C 14 heterocycloalkyl” optionally substituted by one R 1-8 ;

R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 , —C(═O)R 1-3-2 , —C(═NR 1-3-3 )NR 1-3-5 R 1-3-6 , or C 1 -C 7 alkyl;

R 1-3-1 and R 1-3-2 are independently C 1 -C 7 alkyl, or C 3 -C 14 cycloalkyl;

R 1-3-3 is hydrogen;

R 1-3-5 and R 1-3-6 are hydrogen;

R 1-5 is —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or C 3 -C 14 heterocycloalkyl;

R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl;

R 1-5-3 is hydrogen;

R 1-8 is independently oxo;

R 1-9 is independently hydrogen or C 1 -C 7 alkyl;

R 2 is “C 2 -C 7 alkyl or C 3 -C 14 heterocycloalkyl substituted by one R 2-2 ”; R 2-2 is hydroxyl;

scheme (11):

A is

X is CH or N;

R 1 is —CN, —NR 1-3 R 1-4 , —C(═O)R 1-5 , ═N—O—R 1-9 , or “C 3 -C 14 heterocycloalkyl” optionally substituted by one R 1-8 ;

R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 , —C(O)R 1-3-2 , —C(═NR 1-3-3 )NR 1-3-5 R 1-3-6 , or C 1 -C 7 alkyl;

R 1-3-1 and R 1-3-2 are independently C 1 -C 7 alkyl, or C 3 -C 14 cycloalkyl;

R 1-3-3 is hydrogen;

R 1-3-5 and R 1-3-6 are hydrogen;

R 1-5 is —NR 1-5-1 R 1-5-2 , —OR 1-5-3 or C 3 -C 14 heterocycloalkyl; R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl or C 3 -C 14 cycloalkyl; R 1-5-3 is hydrogen or C 1 -C 7 alkyl;

R 1-8 is independently oxo;

R 1-9 is independently hydrogen or C 1 -C 7 alkyl;

R 2 is “C 2 -C 7 alkyl or C 3 -C 14 heterocycloalkyl substituted by one R 2-2 ”; R 2-2 is hydroxyl;

scheme (12):

A is

X is CH or N;

R 1 is independently —CN, —NR 1-3 R 1-4 , —C(═O)R 1-5 , ═N—O—R 1-9 , or “C 3 -C 14 heterocycloalkyl” optionally substituted by one R 1-8 ;

R 1-3 and R 1-4 are independently hydrogen, —S(═O) 2 R 1-3-1 , —C(═O)R 1-3-2 , —C(═NR 1-3-3 )NR 1-3-5 R 1-3-6 , or C 1 -C 7 alkyl;

R 1-3-1 and R 1-3-2 are independently C 1 -C 7 alkyl, or C 3 -C 14 cycloalkyl;

R 1-3-3 is hydrogen;

R 1-3-5 and R 1-3-6 are hydrogen;

R 1-5 is independently —NR 1-5-1 R 1-5-2 , —OR 1-5-3 , or C 3 -C 14 heterocycloalkyl;

R 1-5-1 and R 1-5-2 are independently hydrogen, C 1 -C 7 alkyl, or C 3 -C 14 cycloalkyl;

R 1-5-3 is independently hydrogen or C 1 -C 7 alkyl;

R 1-8 is independently oxo;

R 1-9 is independently hydrogen or C 1 -C 7 alkyl;

R 2 is

12 . The pyrazolone-fused pyrimidine compound represented by formula II according to claim 1 , the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof, wherein, the pyrazolone-fused pyrimidine compound represented by formula II is a compound selected from scheme A, scheme B, scheme C, scheme D, scheme E, scheme F, and scheme G:

scheme A:

scheme B:

its 1 H NMR (400 MHz, MeOD) is δ 8.85 (s, 1H), 8.00 (t, J=7.9 Hz, 1H), 7.80 (d, J=8.1 Hz, 1H), 7.68 (d, J=7.7 Hz, 1H), 7.62 (d, J=8.6 Hz, 2H), 7.28 (d, J=8.6 Hz, 2H), 5.78-5.68 (m, 1H), 5.06 (d, J=10.3 Hz, 1H), 4.95 (s, 1H), 4.82 (s, 2H), 3.82-3.76 (m, 1H), 2.81 (s, 1H), 2.71 (s, 3H), 2.49 (s, 1H), 2.08 (d, J=10.9 Hz, 3H), 1.94 (d, J=15.0 Hz, 3H), 1.72 (s, 4H), 1.59 (d, J=7.0 Hz, 6H);

its 1 H NMR (400 MHz, CDCl 3 ) is δ 8.87 (d, J=2.1 Hz, 1H), 7.91 (td, J=7.9, 1.5 Hz, 1H), 7.78 (d, J=8.0 Hz, 1H), 7.54 (t, J=7.9 Hz, 2H), 7.39 (d, J=7.7 Hz, 1H), 7.21 (d, J=8.5 Hz, 2H), 5.72 (ddt, J=16.4, 10.2, 6.2 Hz, 1H), 5.07 (dd, J=10.2, 1.1 Hz, 1H), 4.96 (dd, J=17.1, 1.2 Hz, 1H), 4.77 (d, J=6.2 Hz, 2H), 4.25-4.10 (m, 2H), 3.95 (s, 1H), 2.73 (s, 1H), 2.56 (dt, J=15.5, 10.8 Hz, 1H), 2.28 (d, J=7.9 Hz, 1H), 2.14 (d, J=10.6 Hz, 1H), 2.05-1.97 (m, 1H), 1.78 (dd, J=19.0, 8.5 Hz, 1H), 1.67 (dt, J=10.1, 6.1 Hz, 3H), 1.61 (s, 6H), 1.59-1.44 (m, 1H), 1.34-1.26 (m, 3H);

its H NMR (400 MHz, MeOD) is δ 8.84 (d, J=1.4 Hz, 1H), 8.00 (td, J=7.9, 4.0 Hz, 1H), 7.83-7.76 (m, 1H), 7.67 (dd, J=7.7, 0.7 Hz, 1H), 7.60 (dd, J=8.4, 5.7 Hz, 2H), 7.19 (dd, J=13.2, 8.6 Hz, 2H), 5.73 (ddd, J=17.0, 6.1, 4.1 Hz, 1H), 5.08-5.03 (m, 1H), 4.95 (d, J=1.3 Hz, 1H), 4.86-4.79 (m, 2H), 2.72 (s, 1H), 2.58 (s, 1H), 2.27 (d, J=6.7 Hz, 1H), 2.13 (d, J=10.0 Hz, 1H), 1.96 (d, J=10.2 Hz, 1H), 1.80-1.66 (m, 4H), 1.64-1.52 (m, 7H);

its 1 H NMR (400 MHz, CDCl 3 ) is δ 8.86 (d, J=4.2 Hz, 1H), 7.97-7.88 (m, 1H), 7.79 (d, J=8.0 Hz, 1H), 7.53 (dd, J=12.3, 8.5 Hz, 2H), 7.39 (d, J=7.6 Hz, 1H), 7.28-7.15 (m, 2H), 5.80-5.65 (m, 1H), 5.06 (d, J=10.0 Hz, 1H), 4.95 (d, J=17.1 Hz, 1H), 4.77 (d, J=6.0 Hz, 2H), 3.10 (d, J=12.1 Hz, 3H), 2.98 (s, 3H), 2.67-2.57 (m, 1H), 2.14 (dd, J=20.9, 10.3 Hz, 1H), 2.06-1.97 (m, 2H), 1.92 (d, J=14.0 Hz, 1H), 1.78-1.66 (m, 4H), 1.61 (s, 6H), 1.49 (dd, J=22.8, 12.2 Hz, 1H);

its 1 H NMR (400 MHz, CDCl 3 ) is δ 8.85 (d, J=4.7 Hz, 1H), 7.91 (dt, J=10.7, 7.9 Hz, 1H), 7.78 (d, J=7.8 Hz, 1H), 7.53 (dd, J=12.0, 8.5 Hz, 2H), 7.39 (dd, J=7.6, 2.4 Hz, 1H), 7.22 (dd, J=19.5, 8.5 Hz, 2H), 5.71 (ddt, J=16.4, 10.2, 6.2 Hz, 1H), 5.06 (d, J=10.2 Hz, 1H), 4.95 (d, J=17.1 Hz, 1H), 4.77 (d, J=6.1 Hz, 2H), 4.21 (dd, J=16.4, 8.6 Hz, 2H), 4.10-4.02 (m, 2H), 2.63-2.52 (m, 2H), 2.35-2.20 (m, 2H), 2.15-2.07 (m, 1H), 2.00 (dd, J=13.4, 3.0 Hz, 2H), 1.92-1.83 (m, 1H), 1.79-1.63 (m, 4H), 1.60 (s, 6H), 1.48 (ddd, J=24.7, 12.5, 2.5 Hz, 1H);

its 1 H NMR (400 MHz, CDCl 3 ) is δ 8.86 (s, 1H), 7.93-7.85 (m, 1H), 7.78 (d, J=7.8 Hz, 1H), 7.52 (d, J=8.5 Hz, 2H), 7.39 (dd, J=7.6, 0.7 Hz, 1H), 7.19 (d, J=8.5 Hz, 2H), 5.71 (ddt, J=16.4, 10.2, 6.2 Hz, 1H), 5.05 (dd, J=10.2, 1.1 Hz, 1H), 4.94 (dd, J=17.1, 1.3 Hz, 1H), 4.77 (d, J=6.2 Hz, 2H), 4.11 (d, J=8.9 Hz, 1H), 3.24 (t, J=7.0 Hz, 4H), 2.52-2.43 (m, 1H), 2.14-2.00 (m, 3H), 1.92 (d, J=11.2 Hz, 4H), 1.60 (s, 6H), 1.45 (dt, J=14.9, 7.5 Hz, 2H), 1.23-1.08 (m, 2H);

its 1 H NMR (400 MHz, CDCl 3 ) is δ 8.84 (d, J=3.7 Hz, 1H), 7.94 (dd, J=14.8, 6.9 Hz, 1H), 7.76 (d, J=7.9 Hz, 1H), 7.58-7.50 (m, 2H), 7.42 (dd, J=7.5, 4.1 Hz, 1H), 7.22 (dd, J=15.8, 8.5 Hz, 2H), 5.71 (dd, J=11.5, 5.4 Hz, 2H), 5.07 (d, J=10.2 Hz, 1H), 4.95 (d, J=17.1 Hz, 1H), 4.77 (d, J=6.1 Hz, 2H), 2.82-2.72 (m, 1H), 2.60 (s, 1H), 2.12-2.01 (m, 3H), 1.92 (d, J=12.5 Hz, 1H), 1.81-1.67 (m, 3H), 1.62 (s, 6H), 1.54-1.43 (m, 1H), 0.93-0.78 (m, 3H), 0.52 (s, 2H);

its 1 H NMR (400 MHz, CDCl 3 ) is δ 8.88 (s, 1H), 7.91 (t, J=7.9 Hz, 1H), 7.77 (d, J=7.9 Hz, 1H), 7.56 (d, J=8.5 Hz, 2H), 7.40 (d, J=7.4 Hz, 1H), 7.19 (d, J=8.5 Hz, 2H), 5.78-5.66 (m, 1H), 5.07 (dd, J=10.2, 1.0 Hz, 1H), 4.96 (dd, J=17.1, 1.2 Hz, 1H), 4.77 (d, J=6.2 Hz, 2H), 4.42 (d, J=7.6 Hz, 1H), 3.49-3.35 (m, 1H), 3.04 (s, 3H), 2.57-2.46 (m, 1H), 2.29-2.17 (m, 2H), 2.05-1.96 (m, 8H), 1.56-1.65 (m, 2H), 1.41-1.50 (m, 2H);

its 1 H NMR (400 MHz, MeOD) is δ 8.84 (s, 1H), 8.02 (m, 1H), 7.80 (m, 1H), 7.72-7.58 (m, 3H), 7.25 (m, 2H), 5.73 (ddt, J=16.5, 10.3, 6.1 Hz, 1H), 5.05 (dd, J=10.2, 1.0 Hz, 1H), 4.95 (d, 1H), 4.83 (d, J=6.1 Hz, 2H), 3.54-3.42 (m, 1H), 2.59 (m, 1H), 2.14 (m, 1H), 1.98 (m, 2H), 1.83 (m, 1H), 1.68 (m, 2H), 1.60 (s, 6H), 1.50 (m, 2H);

its 1 H NMR (400 MHz, DMSO) is δ 10.28 (s, 1H), 8.88 (d, J=1.8 Hz, 1H), 8.09-7.97 (m, 1H), 7.75 (d, J=8.4 Hz, 1H), 7.66 (dd, J=20.6, 8.5 Hz, 3H), 7.19 (dd, J=11.1, 8.7 Hz, 2H), 5.74-5.61 (m, 1H), 5.00 (d, J=10.2 Hz, 1H), 4.82 (d, J=17.1 Hz, 1H), 4.69 (d, J=5.5 Hz, 2H), 3.23 (s, 1H), 2.74 (t, J=12.1 Hz, 1H), 2.53 (s, 1H), 2.12 (d, J=10.1 Hz, 1H), 1.98 (d, J=13.2 Hz, 1H), 1.82 (d, J=13.2 Hz, 2H), 1.77-1.57 (m, 3H), 1.49 (d, J=18.2 Hz, 6H);

its 1 H NMR (400 MHz, DMSO) is δ 10.27 (s, 1H), 8.89 (s, 1H), 8.12 (s, 1H), 7.74 (dd, J=22.6, 8.3 Hz, 3H), 7.64 (d, J=7.3 Hz, 1H), 7.37 (d, J=8.5 Hz, 2H), 5.76-5.61 (m, 1H), 5.34 (s, 1H), 5.01 (dd, J=10.3, 1.2 Hz, 1H), 4.84 (d, J=17.1 Hz, 1H), 4.70 (d, J=5.7 Hz, 2H), 3.62 (s, 1H), 3.12 (s, 1H), 2.71-2.58 (m, 8H), 2.38 (d, J=9.2 Hz, 2H), 1.47 (s, 6H), 1.32-1.24 (m, 1H);

its 1 H NMR (400 MHz, DMSO) is δ 10.26 (s, 1H), 8.88 (s, 1H), 8.07 (t, J=7.8 Hz, 1H), 7.76 (d, J=8.0 Hz, 1H), 7.65 (dd, J=14.5, 7.9 Hz, 2H), 7.22 (d, J=8.5 Hz, 2H), 5.74-5.60 (m, 1H), 5.35 (s, 1H), 5.00 (d, J=10.3 Hz, 1H), 4.83 (d, J=17.1 Hz, 1H), 4.69 (d, J=5.6 Hz, 2H), 3.74 (s, 3H), 3.24-3.15 (m, 1H), 2.77 (t, J=12.0 Hz, 1H), 2.37 (d, J=14.0 Hz, 1H), 2.25 (td, J=13.4, 4.6 Hz, 1H), 1.99-1.84 (m, 3H), 1.67-1.50 (m, 2H), 1.49 (d, J=14.0 Hz, 6H);

its 1 H NMR (400 MHz, MeOD) is δ 8.86 (s, OH), 8.11-8.01 (m, 1H), 7.94 (d, J=7.9 Hz, 2H), 7.67 (d, J=7.6 Hz, 2H), 7.62 (d, J=8.6 Hz, 2H), 7.28 (d, J=8.5 Hz, 2H), 5.83-5.74 (m, 1H), 5.09 (dd, J=7.9, 4.4 Hz, 3H), 4.98 (dd, J=17.1, 1.3 Hz, 2H), 4.85 (d, J=6.7 Hz, 2H), 2.87 (s, 1H), 2.64 (s, 1H), 2.47 (s, 3H), 1.97-1.67 (m, 8H);

its 1 H NMR (400 MHz, MeOD) is δ 8.87 (d, J=6.6 Hz, 1H), 8.06 (t, J=7.9 Hz, 1H), 7.95 (d, J=7.9 Hz, 1H), 7.68 (dd, J=7.8, 5.4 Hz, 2H), 7.61 (d, J=8.6 Hz, 1H), 7.41 (d, J=8.4 Hz, 1H), 7.24 (t, J=8.7 Hz, 1H), 5.84-5.72 (m, 1H), 5.09 (d, J=6.2 Hz, 2H), 5.07 (d, J=1.3 Hz, 1H), 5.02-4.94 (m, 2H), 4.90 (s, 2H), 4.84 (d, J=6.7 Hz, 2H), 3.15 (d, J=2.6 Hz, 1H), 3.08 (s, 1H), 2.95 (s, 1H), 2.71 (s, 1H), 2.43 (s, 1H), 1.93-2.03 (m, 3H), 1.76 (s, 2H), 1.51 (s, 1H), 1.31 (d, J=4.3 Hz, 3H), 0.89 (dd, J=20.1, 9.0 Hz, 4H);

its 1 H NMR (400 MHz, CDCl 3 ) is δ 8.87-8.79 (m, 1H), 8.14-8.07 (m, 1H), 8.04-7.96 (m, 1H), 7.89-7.80 (m, 1H), 7.61-7.50 (m, 2H), 7.38-7.32 (m, 1H), 7.25-7.19 (m, 1H), 7.01 (t, J=3.4 Hz, 1H), 5.72 (ddd, J=16.6, 11.1, 8.6 Hz, 1H), 5.17-5.09 (m, 2H), 5.04-4.98 (m, 1H), 4.98-4.92 (m, 1H), 4.87-4.77 (m, 2H), 4.73-4.64 (m, 2H), 4.20-4.06 (m, 1H), 3.47-3.38 (m, 1H), 3.38-3.29 (m, 1H), 3.05-2.98 (m, 1H), 2.49-2.35 (m, 2H), 2.27-2.17 (m, 1H), 2.07-1.86 (m, 4H), 1.75-1.60 (m, 3H);

its 1 H NMR (400 MHz, CDCl 3 ) is δ 8.77 (s, 1H), 8.16-8.07 (m, 1H), 8.03 (d, J=7.6 Hz, 1H), 7.83-7.75 (m, 1H), 7.56 (dd, J=12.6, 6.1 Hz, 2H), 7.33 (d, J=8.5 Hz, 1H), 7.21 (d, J=8.5 Hz, 1H), 5.72 (dd, J=17.0, 10.3 Hz, 1H), 5.13 (dd, J=9.1, 6.1 Hz, 2H), 4.96 (d, J=17.0 Hz, 2H), 4.81 (d, J=7.2 Hz, 2H), 4.69 (d, J=6.2 Hz, 2H), 4.41-4.28 (m, 2H), 3.86 (s, 1H), 3.77 (t, J=6.6 Hz, 1H), 3.63-3.50 (m, 2H), 2.98 (m, 1H), 2.15 (m, 1H), 1.97 (dd, J=18.9, 9.6 Hz, 2H), 1.78 (d, J=5.0 Hz, 2H), 1.65 (d, J=8.7 Hz, 2H);

its 1 H NMR (400 MHz, CDCl 3 ) is δ 8.69 (s, 1H), 8.18 (d, J=8.0 Hz, 1H), 8.10 (dd, J=17.9, 7.6 Hz, 1H), 7.81-7.72 (m, 1H), 7.63-7.49 (m, 2H), 7.25 (d, J=8.4 Hz, 1H), 7.19 (d, J=8.3 Hz, 1H), 5.70 (d, J=6.8 Hz, 1H), 5.15 (d, J=10.1 Hz, 1H), 5.14-5.07 (m, 1H), 4.95 (d, J=16.6 Hz, 1H), 4.83 (t, J=6.7 Hz, 2H), 4.71 (s, 2H), 2.54 (dd, J=24.9, 12.6 Hz, 2H), 2.30 (d, J=11.2 Hz, 1H), 2.18 (d, J=13.5 Hz, 1H), 2.02 (d, J=12.9 Hz, 1H), 1.96-1.80 (m, 2H), 1.78 (d, J=16.1 Hz, 1H), 1.49 (dd, J=26.4, 11.2 Hz, 2H);

its 1 H NMR (400 MHz, Methanol-d 4 ) is δ 8.85 (d, J=1.1 Hz, 1H), 8.05 (td, J=7.9, 4.8 Hz, 1H), 7.96-7.86 (m, 1H), 7.67 (d, J=7.6 Hz, 1H), 7.59 (ddd, J=9.2, 4.6, 2.3 Hz, 2H), 7.25-7.19 (m, 1H), 7.19-7.11 (m, 1H), 5.78 (ddt, J=16.5, 10.1, 6.1 Hz, 1H), 5.12-5.07 (m, 2H), 5.06 (t, J=1.3 Hz, 1H), 4.98 (dd, J=17.0, 1.4 Hz, 1H), 4.90 (d, J=1.4 Hz, 2H), 4.25-4.19 (m, 1H), 4.14 (dd, J=14.1, 7.1 Hz, 1H), 2.34-2.12 (m, 2H), 2.07 (dd, J=17.0, 4.1 Hz, 1H), 1.99-1.82 (m, 1H), 1.74-1.65 (m, 2H), 1.65-1.53 (m, 2H), 1.31 (d, J=4.2 Hz, 3H), 1.29-1.25 (m, 2H);

its 1 H NMR (400 MHz, Methanol-d 4 ) is δ 8.84 (s, 1H), 8.05 (t, J=7.9 Hz, 1H), 7.92 (d, J=8.1 Hz, 1H), 7.66 (dd, J=7.6, 0.9 Hz, 1H), 7.63-7.53 (m, 2H), 7.22-7.14 (m, 2H), 5.84-5.74 (m, 1H), 5.10-5.07 (m, 2H), 5.06 (q, J=1.3 Hz, 1H), 4.98 (dq, J=17.0, 1.4 Hz, 1H), 4.89 (dt, J=6.1, 1.4 Hz, 2H), 2.71 (d, J=6.9 Hz, 1H), 2.59 (s, 1H), 2.24 (dd, J=16.4, 7.8 Hz, 2H), 2.04 (d, J=8.5 Hz, 1H), 1.73 (td, J=10.9, 6.8 Hz, 6H);

scheme C:

scheme D:

(I-1-1), its 1 H NMR (400 MHz, MeOD) is δ 8.85 (s, 1H), 8.46 (s, 2H), 7.99 (t, J=7.9 Hz, 1H), 7.79 (d, J=8.0 Hz, 1H), 7.65 (dd, J=16.6, 8.1 Hz, 3H), 7.22 (d, J=8.6 Hz, 2H), 5.73 (ddt, J=16.3, 10.2, 6.1 Hz, 1H), 5.05 (dd, J=10.3, 1.1 Hz, 1H), 4.93 (dd, J=17.1, 1.3 Hz, 1H), 4.82 (d, J=6.1 Hz, 2H), 2.90 (s, 6H), 2.60 (d, J=8.4 Hz, 1H), 2.21 (s, 2H), 2.10 (d, J=10.6 Hz, 2H), 1.70 (d, J=11.4 Hz, 4H), 1.59 (s, 6H);

(I-1-2), its 1 H NMR (400 MHz, CDCl 3 ) is δ 8.86 (s, 1H), 8.54 (s, 1H), 7.95 (t, J=7.9 Hz, 1H), 7.75 (d, J=8.0 Hz, 1H), 7.59 (d, J=8.5 Hz, 2H), 7.43 (d, J=7.6 Hz, 1H), 7.32 (d, J=8.5 Hz, 2H), 5.72 (ddt, J=16.5, 10.3, 6.2 Hz, 1H), 5.06 (d, J=10.2 Hz, 1H), 4.95 (dd, J=17.1, 1.0 Hz, 1H), 4.75 (d, J=6.1 Hz, 2H), 3.05 (m, 1H), 2.93 (m, 1H), 2.68 (s, 6H), 2.32 (m, 2H), 1.84 (m, 6H), 1.60 (s, 6H);

(I-3-1), its 1 H NMR (400 MHz, CDCl 3 ) is δ 8.87 (s, 1H), 7.90 (t, J=7.9 Hz, 1H), 7.78 (d, J=8.0 Hz, 1H), 7.53 (d, J=8.5 Hz, 2H), 7.39 (dd, J=7.6, 0.5 Hz, 1H), 7.20 (d, J=8.5 Hz, 2H), 5.72 (ddt, J=16.4, 10.2, 6.2 Hz, 1H), 5.06 (dd, J=10.2, 1.0 Hz, 1H), 4.95 (dd, J=17.1, 1.2 Hz, 1H), 4.76 (d, J=6.2 Hz, 2H), 4.04 (s, 1H), 2.66 (m, 4H), 2.58-2.47 (m, 1H), 2.16 (m, 4H), 1.96 (m, 2H), 1.87-1.78 (m, 4H), 1.60 (s, 6H), 1.58-1.39 (m, 4H);

(I-3-2), its 1 H NMR (400 MHz, CDCl 3 ) is δ 8.87 (s, 1H), 7.92 (t, J=7.9 Hz, 1H), 7.80 (d, J=8.0 Hz, 1H), 7.52 (d, J=8.5 Hz, 2H), 7.38 (d, J=7.6 Hz, 1H), 7.29 (t, J=4.2 Hz, 2H), 5.79-5.66 (m, 1H), 5.06 (dd, J=10.2, 1.0 Hz, 1H), 4.96 (dd, J=17.1, 1.2 Hz, 1H), 4.77 (d, J=6.2 Hz, 2H), 4.02 (s, 1H), 2.70-2.50 (m, 5H), 2.26 (s, 1H), 1.98 (m, 4H), 1.82 (s, 4H), 1.69-1.56 (m, 10H);

(I-8-1), its 1 H NMR (400 MHz, CDCl 3 ) is δ 8.86 (s, 1H), 7.93-7.85 (m, 1H), 7.78 (d, J=7.8 Hz, 1H), 7.52 (d, J=8.5 Hz, 2H), 7.39 (dd, J=7.6, 0.7 Hz, 1H), 7.19 (d, J=8.5 Hz, 2H), 5.71 (ddt, J=16.4, 10.2, 6.2 Hz, 1H), 5.05 (dd, J=10.2, 1.1 Hz, 1H), 4.94 (dd, J=17.1, 1.3 Hz, 1H), 4.77 (d, J=6.2 Hz, 2H), 4.11 (d, J=8.9 Hz, 1H), 3.24 (t, J=7.0 Hz, 4H), 2.52-2.43 (m, 1H), 2.14-2.00 (m, 3H), 1.92 (d, J=11.2 Hz, 4H), 1.60 (s, 6H), 1.45 (dt, J=14.9, 7.5 Hz, 2H), 1.23-1.08 (m, 2H);

(I-8-2), its 1 H NMR (400 MHz, CDCl 3 ) is δ8.87 (s, 1H), 7.92 (d, J=7.8 Hz, 1H), 7.80 (d, J=8.0 Hz, 1H), 7.52 (d, J=8.4 Hz, 2H), 7.39 (d, J=7.6 Hz, 1H), 7.29-7.25 (m, 2H), 5.82-5.63 (m, 1H), 5.12-4.91 (m, 2H), 4.78 (d, J=6.2 Hz, 2H), 4.01 (s, 1H), 3.17 (s, 4H), 2.53 (s, 1H), 2.33 (s, 1H), 2.06 (d, J=4.4 Hz, 2H), 1.89 (d, J=11.6 Hz, 2H), 1.75 (d, J=14.1 Hz, 2H), 1.59 (d, J=17.2 Hz, 8H), 1.46 (t, J=13.1 Hz, 2H);

(I-15-1), its 1 H NMR (400 MHz, MeOD) is δ 8.84 (s, 1H), 8.04 (t, J=7.9 Hz, 1H), 7.92 (d, J=8.1 Hz, 1H), 7.67 (d, J=7.6 Hz, 1H), 7.60 (d, J=8.6 Hz, 2H), 7.21 (d, J=8.6 Hz, 2H), 5.78 (ddt, J=16.3, 10.3, 6.1 Hz, 1H), 5.12-5.05 (m, 3H), 4.98 (dd, J=17.1, 1.3 Hz, 1H), 4.89 (d, J=6.1 Hz, 2H), 4.84 (s, 2H), 3.68 (s, 2H), 2.97-2.86 (m, 1H), 2.66 (s, 6H), 2.60-2.50 (m, 1H), 2.15 (d, J=8.6 Hz, 2H), 2.04 (d, J=9.0 Hz, 2H), 1.66-1.54 (m, 4H);

(I-15-2), its 1 H NMR (400 MHz, MeOD) is δ 8.83 (s, 1H), 8.04 (t, J=7.9 Hz, 1H), 7.92 (d, J=8.0 Hz, 1H), 7.67-7.62 (m, 1H), 7.59 (d, J=8.6 Hz, 2H), 7.29 (d, J=8.5 Hz, 2H), 5.76 (ddt, J=16.3, 10.2, 6.1 Hz, 1H), 5.10-5.02 (m, 3H), 4.96 (dd, J=17.1, 1.3 Hz, 1H), 4.87 (d, J=6.8 Hz, 2H), 4.82 (d, J=6.8 Hz, 2H), 2.73 (d, J=4.2 Hz, 1H), 2.29 (d, J=21.9 Hz, 7H), 2.04-1.90 (m, 4H), 1.66 (dd, J=15.6, 6.1 Hz, 4H);

(I-36-1), its 1 H NMR (400 MHz, CDCl 3 ) is δ 8.88 (d, J=2.6 Hz, 1H), 8.09 (dd, J=15.0, 7.8 Hz, 1H), 7.99-7.83 (m, 2H), 7.54 (t, J=9.5 Hz, 2H), 7.39 (d, J=8.7 Hz, 1H), 7.21 (d, J=8.5 Hz, 1H), 5.74 (dq, J=10.5, 5.9 Hz, 1H), 5.12 (t, J=8.8 Hz, 3H), 4.99 (d, J=17.1 Hz, 1H), 4.80 (d, J=6.3 Hz, 2H), 4.67 (d, J=6.0 Hz, 2H), 3.39-3.24 (m, 4H), 2.60-2.34 (m, 3H), 2.14 (dt, J=14.0, 6.8 Hz, 3H), 1.96 (d, J=10.8 Hz, 4H), 1.55-1.37 (m, 2H), 1.27-1.12 (m, 2H);

(I-36-2), its 1 H NMR (400 MHz, MeOD) is δ 8.86 (s, 1H), 8.02 (dt, J=24.0, 7.9 Hz, 3H), 7.64 (dd, J=27.1, 8.1 Hz, 3H), 7.27 (t, J=8.6 Hz, 2H), 7.01-6.91 (m, 3H), 6.72-6.64 (m, 3H), 5.79 (ddd, J=16.3, 11.2, 6.1 Hz, 1H), 5.10-5.05 (m, 2H), 4.85 (d, J=6.8 Hz, 2H), 2.57 (d, J=10.7 Hz, 1H), 2.48-2.28 (m, 3H), 2.23-2.06 (m, 3H), 1.98-1.71 (m, 6H), 1.58 (dd, J=23.2, 12.9 Hz, 3H), 1.44 (ddd, J=16.1, 13.2, 3.5 Hz, 2H), 1.19-1.00 (m, 2H);

(I-41-1), its 1 H NMR (400 MHz, Chloroform-d) is δ 9.00 (s, 1H), 8.30 (d, J=8.6 Hz, 1H), 8.22 (d, J=2.4 Hz, 1H), 7.96 (t, J=7.9 Hz, 1H), 7.73 (dd, J=8.1, 0.8 Hz, 1H), 7.55 (dd, J=8.7, 2.4 Hz, 1H), 7.44 (dd, J=7.7, 0.8 Hz, 1H), 5.77-5.66 (m, 1H), 5.12-5.05 (m, 1H), 4.97 (dq, J=17.0, 1.4 Hz, 1H), 4.76 (dt, J=6.3, 1.3 Hz, 2H), 2.70 (s, 1H), 2.56 (s, 6H), 2.23 (q, J=9.5 Hz, 4H), 2.11-2.01 (m, 4H), 1.58 (t, J=10.3 Hz, 6H);

(I-41-2), its 1 H NMR (400 MHz, Chloroform-d) is δ8.99 (s, 1H), 8.54 (s, 1H), 8.32 (d, J=8.7 Hz, 1H), 8.26 (d, J=2.4 Hz, 1H), 8.10 (t, J=7.7 Hz, 1H), 7.92 (s, 1H), 7.78 (dd, J=8.1, 0.8 Hz, 1H), 7.47-7.41 (m, 1H), 5.79-5.71 (m, 1H), 5.08 (dq, J=10.1, 1.2 Hz, 1H), 4.97 (dq, J=17.0, 1.3 Hz, 1H), 4.77 (dt, J=6.2, 1.4 Hz, 2H), 3.99 (s, 1H), 2.75 (d, J=11.0 Hz, 1H), 2.52 (s, 6H), 2.32-2.18 (m, 1H), 2.09 (d, J=14.4 Hz, 4H), 1.31 (d, J=22.8 Hz, 4H);

wherein, means an uncertain cis-trans conformation;

scheme E:

(I-8-1), its 1 H NMR (400 MHz, CDCl 3 ) has a peak of 1.23-1.08;

wherein, means an uncertain cis-trans conformation;

scheme F:

(I-1-1) with a retention time of 10.55 min under conditions comprising: Agilent 1260 high performance liquid chromatograph; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; column time: 15 min; column type: Waters' Xselect, 5 μm, 4.6×250 mm; gradient elution, 5% mobile phase B→50% mobile phase B;

(I-1-2) with a retention time of 10.78 min under conditions comprising: Agilent 1260 high performance liquid chromatograph; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; column time: 15 min; column type: Waters' Xselect, 5 μm, 4.6×250 mm; gradient elution, 5% mobile phase B→50% mobile phase B;

(I-3-1) with a retention time of 11.01 min under conditions comprising: Agilent 1260 high performance liquid chromatograph; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; column time: 15 min; column type: Waters' Xselect, 5 μm, 4.6×250 mm; gradient elution, 5% mobile phase B→50% mobile phase B;

(I-3-2) with a retention time of 11.20 min under conditions comprising: Agilent 1260 high performance liquid chromatograph; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; column time: 15 min; column type: Waters' Xselect, 5 μm, 4.6×250 mm; gradient elution, 5% mobile phase B→50% mobile phase B;

(I-8-1) with a retention time of 10.78 min under conditions comprising: Agilent 1260 high performance liquid chromatograph; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; column time: 15 min; column type: Waters' Xselect, 5 μm, 4.6×250 mm; gradient elution, 5% mobile phase B→50% mobile phase B;

(I-8-2) with a retention time of 11.00 min under the following conditions: Agilent 1260 high performance liquid chromatograph; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; column time: 15 min; column type: Waters' Xselect, 5 μm, 4.6×250 mm; gradient elution, 5% mobile phase B→50% mobile phase B;

(I-15-1) with a retention time of 7.02 min under conditions comprising: Agilent 1260 high performance liquid chromatograph; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; column time: 15 min; column type: Waters' Xselect, 5 μm, 4.6×250 mm; gradient elution, 5% mobile phase B→95% mobile phase B;

(I-15-2) with a retention time of 7.16 min under conditions comprising: Agilent 1260 high performance liquid chromatograph; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; column time: 15 min; column type: Waters' Xselect, 5 μm, 4.6×250 mm; gradient elution, 5% mobile phase B→95% mobile phase B;

(I-36-1) with a retention time of 7.14 min under conditions comprising: Agilent 1260 high performance liquid chromatograph; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; column time: 15 min; column type: Waters' Xselect, 5 μm, 4.6×250 mm; gradient elution, 5% mobile phase B→95% mobile phase B;

(I-36-2) with a retention time of 7.15 min under conditions comprising: Agilent 1260 high performance liquid chromatograph; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; column time: 15 min; column type: Waters' Xselect, 5 μm, 4.6×250 mm; gradient elution, 5% mobile phase B→95% mobile phase B;

(I-41-1) with a retention time of 6.17 min under conditions comprising: Agilent 1260 high performance liquid chromatograph; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; column time: 15 min; column type: Waters' Xselect, 5 μm, 4.6×250 mm; gradient elution, 5% mobile phase B→95% mobile phase B;

(I-41-2) with a retention time of 6.28 min under conditions comprising: Agilent 1260 high performance liquid chromatograph; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; column time: 15 min; column type: Waters' Xselect, 5 μm, 4.6×250 mm; gradient elution, 5% mobile phase B→95% mobile phase B;

wherein, means that the cis-trans conformation is uncertain;

scheme G:

13 . A preparation method of the pyrazolone-fused pyrimidine compound represented by formula II according to claim 1 , the method is method 1 or method 2:

method 1, comprising: step I, oxidizing compound II-1A by an oxidant in an organic solvent to obtain compound II-1B; and step II, reacting compound II-1B with compound II-1C in an organic solvent and under alkaline conditions to obtain compound II;

method 2, comprising: step I, hydrolyzing compound II-2A (R 1 is —(C═O)—O—C 2 H 5 ) to obtain compound II-2B (R 1 is —(C═O)—OH); and step II, a condensation reaction is carried out between compound II-2B and an amino compound in an organic solvent to obtain compound II (R 1 is —(C═O)—NR 1-5-1 R 1-5-2 );

14 . A pharmaceutical composition comprising a substance X and a pharmaceutical excipient;

the substance X is the pyrazolone-fused pyrimidine compound represented by formula II according to claim 1 , the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof.

15 . A combination comprising a substance X and an anticancer drug,

the substance X is the pyrazolone-fused pyrimidine compound represented by formula II according to claim 1 , the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof.

16 . The pyrazolone-fused pyrimidine compound represented by formula II according to claim 12 or the pharmaceutically acceptable salt thereof, wherein, the pyrazolone-fused pyrimidine compound represented by formula II is I-8:

17 . The pyrazolone-fused pyrimidine compound represented by formula II according to claim 12 or the pharmaceutically acceptable salt thereof, wherein, the pyrazolone-fused pyrimidine compound represented by formula II is I-8-1:

18 . The pyrazolone-fused pyrimidine compound represented by formula II according to claim 12 or the pharmaceutically acceptable salt thereof, wherein, the pyrazolone-fused pyrimidine compound represented by formula II is I-23:

19 . The pyrazolone-fused pyrimidine compound represented by formula II according to claim 12 or the pharmaceutically acceptable salt thereof, wherein, the pyrazolone-fused pyrimidine compound represented by formula II is I-15-1:

20 . A method for inhibiting WEE1 kinase in a subject, comprising administering a therapeutically effective amount of a substance X to the subject;

the substance X is the pyrazolone-fused pyrimidine compound represented by formula II according to claim 1 , the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, the metabolite thereof or the prodrug thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2021
From: WANG, QIAN; SHU, SIJIE; XIA, GUANGXIN; GE, HUI; ZHANG, BINGBIN; HUO, GUOYONG; ZHANG, LIN; SHI, CHEN; LOU, JIANGSONG; ZHANG, CHI; ZHANG, ZHIHUI; MAO, YU; YU, JIANXIN; KE, YING; LIU, YANJUN
To: SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.
Reel/Frame 058473/0040 →
Priority Claims (1)
CN 201910579671.0 · Jun 28, 2019 · national
Continuity (1)
Related Publication 20220259210A1 · Aug 18, 2022
References Cited (80)
US 7241763B2 · Lacrampe et al. · 2007 [cited by applicant]
US 7834019B2 · Sagara et al. · 2010 [cited by applicant]
US 7935708B2 · Sagara · 2011 [cited by examiner]
US 7947695B2 · Freyne et al. · 2011 [cited by applicant]
US 8288396B2 · Goto et al. · 2012 [cited by applicant]
US 8507505B2 · Bamba et al. · 2013 [cited by applicant]
US 10766902B2 · Burkamp et al. · 2020 [cited by applicant]
US 10947238B2 · Reigan et al. · 2021 [cited by applicant]
US 10954253B2 · Qian et al. · 2021 [cited by applicant]
US 11124518B2 · Huang et al. · 2021 [cited by applicant]
US 11261192B2 · Huang et al. · 2022 [cited by applicant]
US 11299493B2 · Chakravarty et al. · 2022 [cited by applicant]
US 20100105674A1 · Deanda, Jr. et al. · 2010 [cited by applicant]
US 20100113445A1 · Deanda, Jr. et al. · 2010 [cited by applicant]
US 20200017528A1 · Qian et al. · 2020 [cited by applicant]
US 20210061807A1 · Chen · 2021 [cited by applicant]
CN 101432284A · 2009 [cited by applicant]
CN 109422754A · 2019 [cited by applicant]
CN 109810111A · 2019 [cited by applicant]
WO 2004007499A1 · 2004 [cited by applicant]
WO 2006074985A1 · 2006 [cited by applicant]
WO 2007126122A1 · 2007 [cited by applicant]
WO 2007126128A1 · 2007 [cited by applicant]
WO 2008115738A1 · 2008 [cited by applicant]
WO 2008115742A1 · 2008 [cited by applicant]
WO 2010067886A1 · 2010 [cited by applicant]
WO 2010098367A1 · 2010 [cited by applicant]
WO 2017075629A2 · 2017 [cited by applicant]
WO 2018011569A1 · 2018 [cited by applicant]
WO 2018133829A1 · 2018 [cited by applicant]
WO 2019028008A1 · 2019 [cited by applicant]
WO 2019037678A1 · 2019 [cited by applicant]
WO 2019074979A1 · 2019 [cited by applicant]
WO 2019165204A1 · 2019 [cited by applicant]
WO 2020259703A1 · 2020 [cited by applicant]
Esposito, Francesca, et al. “Wee1 kinase: a potential target to overcome tumor resistance to therapy.” International Journal of Molecular Sciences 22.19 (2021): 10689. (Year: 2021). [cited by examiner]
Wang, Zizhuo, et al. “An update of predictive biomarkers related to WEE1 inhibition in cancer therapy.” Journal of Cancer Research and Clinical Oncology 150.1 (2024): 13. (Year: 2024). [cited by examiner]
American Cancer Society. “Breast Cancer Risk and Prevention”. https://www.cancer.org/content/dam/CRC/PDF/Public/8578.00.pdf. Accessed Apr. 18, 2025. (Year: 2025). [cited by examiner]
American Cancer Society. “Osteosarcoma Caused, Risk Factors, and Prevention”. https://www.cancer.org/content/dam/CRC/PDF/Public/8769.00.pdf. Accessed Apr. 18, 2025. (Year: 2025). [cited by examiner]
National Center for Biotechnology Information. “PubChem Compound Summary for CID 105533627, Ethyl 4-(4-aminophenyl)cyclohexane-1-carboxylate” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Ethyl-4-_4-aminophenyl_cyc… [cited by examiner]
International Search Report for International Patent Application No. PCT/CN2020/098611, mailed Sep. 30, 2020. [cited by applicant]
Written Opinion for International Patent Application No. PCT/CN2020/098611, mailed Sep. 30, 2020. [cited by applicant]
“1780635-51-9”, STN Registry, Jun. 15, 2015 (Jun. 15, 2015), DOI: 20200904173416X. [cited by applicant]
“1700621-59-5”, STN Registry, May 7, 2015 (May 7, 2015), DOI: 20200904173454X. [cited by applicant]
“1935415-74-9”, STN Registry, Jun. 20, 2016 (Jun. 20, 2016), DOI: 20200904173330X. [cited by applicant]
“1780952-51-3”, STN Registry, Jun. 15, 2015 (Jun. 15, 2015), DOI: 20200904173538X. [cited by applicant]
“1391259-46-3”, STN Registry, Aug. 15, 2012 (Aug. 15, 2012), DOI: 20200904173616X. [cited by applicant]
“1391234-19-7”, STN Registry, Aug. 15, 2012 (Aug. 15, 2012), DOI: 20200904173650X. [cited by applicant]
“1391201-09-4”, STN Registry, Aug. 15, 2012 (Aug. 15, 2012), DOI: 20200904173717X. [cited by applicant]
“1391021-25-2”, STN Registry, Aug. 14, 2012 (Aug. 14, 2012), DOI: 20200904173744X. [cited by applicant]
“1049004-35-4”, STN Registry, Sep. 12, 2008 (Sep. 12, 2008), DOI: 20200904173823X. [cited by applicant]
“1049004-05-8”, STN Registry, Sep. 12, 2008 (Sep. 12, 2008), DOI: 20200904173859X. [cited by applicant]
“892492-28-3”, STN Registry, Jul. 13, 2006 (Jul. 13, 2006), DOI: 20200904173934X. [cited by applicant]
“892492-16-9”, STN Registry, Jul. 13, 2006 (Jul. 13, 2006), DOI: 20200904174009X. [cited by applicant]
“854446-70-1”, STN Registry, Jul. 11, 2005 (Jul. 11, 2005), DOI: 20200904174040X. [cited by applicant]
“854446-68-7”, STN Registry, Jul. 11, 2005 (Jul. 11, 2005), DOI: 20200904174106X. [cited by applicant]
“31352-37-1”, STN Registry, Nov. 16, 1984 (Nov. 16, 1984), DOI: 20200904174138X. [cited by applicant]
“62485-63-6”, STN Registry, Nov. 16, 1984 (Nov. 16, 1984), DOI: 20200904174203X. [cited by applicant]
“1780635-51-9”, [cited by applicant]
“1700621-59-5”, [cited by applicant]
“1935415-74-9”, [cited by applicant]
“1780952-51-3”, [cited by applicant]
“1391259-46-3”, [cited by applicant]
“1391234-19-7”, [cited by applicant]
“1391201-09-4”, [cited by applicant]
“1391021-25-2”, [cited by applicant]
“1049004-35-4”, [cited by applicant]
“1049004-05-8”, [cited by applicant]
“892492-28-3”, [cited by applicant]
“892492-16-9”, [cited by applicant]
“854446-70-1”, [cited by applicant]
“854446-68-7”, [cited by applicant]
“31352-37-1”, [cited by applicant]
“62485-63-6”, [cited by applicant]
International Search Report from PCT/CN2020/098611, mailed Sep. 30, 2020 (11 pages, English Translation). [cited by applicant]
Written Opinion of the International Searching Authority from PCT/CN2020/098611, mailed Sep. 30, 2020 (11 pages, English). [cited by applicant]
International Search Report from PCT/CN2020/112034, mailed Nov. 25, 2020 (9 pages, English Translation). [cited by applicant]
Written Opinion of the International Searching Authority from PCT/CN2020/112034, mailed Nov. 25, 2020 (7 pages, English). [cited by applicant]
Berge, et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, vol. 66, No. 1, Jan. 1977, 19 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/CN2020/098611, mailed on Jan. 6, 2022, 21 pages (14 Pages of English Translation and 7 pages of Original Document). [cited by applicant]